9月24日这些公告有看头

Major Events - Shanghai Zhiyuan Hengyue Technology Partnership plans to acquire 37% of Shangwei New Materials at a price of 7.78 yuan per share, with a total funding requirement of 1.161 billion yuan [4] - Yong'an Pharmaceutical intends to acquire 49.2% equity of its subsidiary Ling'an Technology for 27 million yuan, aiming for full control to enhance management and market expansion in the creatine sector [5] - Dongfang Materials received an administrative regulatory decision from the CSRC, requiring rectification of accounting and internal control issues within 30 days [6] - Zhongwei Semiconductor submitted an application for H-share issuance to the Hong Kong Stock Exchange [7] - Kangtai Biological's application for a flu virus split vaccine has been accepted by the National Medical Products Administration, which could enhance the company's market position if approved [8] - Jialiqi plans to transfer 35% equity of Xian Junhui Aviation Technology to a related party for 20.8699 million yuan, resulting in no remaining stake in the company [9] - China Electric Power Construction announced the retirement of Vice Chairman and General Manager Wang Bin due to age, with no impact on board composition [10] Shareholding Changes - Jinma Amusement's chairman completed a share reduction plan, selling 2.43% of the company's shares, totaling 3.8336 million shares [11] Major Contracts - Heng Rui Pharmaceutical signed a licensing agreement for the drug Rykon Trastuzumab, with potential milestone payments up to 1.093 billion USD, enhancing its international market presence [13] - Linyang Energy won a procurement project from the State Grid worth approximately 142 million yuan, expected to positively impact its 2025 and 2026 performance [14] - Sinopec Oilfield Services' subsidiary signed a contract worth 359 million USD for a project in Iraq, representing about 3.15% of the company's 2024 revenue [15]